Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease

Related Keywords

France , United Kingdom , Mexico , United States , Japan , Switzerland , Canada , Swiss , America , American , Patrickj Mcenany , David Schull Russo , Drug Administration , European Medicines Agency , Moelis Company , Investor Contact Mary Coleman Catalyst Pharmaceuticals Inc , Life Science Alliance , Chiesi Group , Japan Should Santhera Pursue Partnership Opportunities , Steering Committee , Health Canada , Catalyst Pharmaceuticals , Santhera Pharmaceuticals Holding , Catalyst Pharmaceuticals Inc , Santhera Pharmaceuticals , Development Rights For Vamorolone , Regulatory Agency , Currently Under Review , Duchenne Muscular Dystrophy , Rare Neuromuscular , Granted Fast Track , Orphan Drug Designation , Treat Duchenne Muscular , Launch Vamorolone , Regulatory Approval , Include Commercial , Future Development Rights , Additional Indications , North America , First Negotiation , Japan Should Santhera Pursue Partnership , Also Includes , Strategic Equity Investment , North American , New Drug Application , Prescription Drug User Fee Act , Orphan Drug , Fast Track , Rare Pediatric Disease , Joint Steering Committee , Promising Innovative Medicine , Proc Natl Acad Sci United States , United Kingdom Medicines , Full Prescribing , Safety Information , Full Prescribing Information , Annual Report , Quarterly Report , Contact David Schull Russo Partners ,